Table 1.
Sensitivity, specificity, PLR, NLR and OR of the blood-based SEPT9 gene methylation assay in CRC detection or screening with various algorithm.
| Publications | Number of cases | Sensitivity | Specificity | PLR | NLR | OR | Algorithm | Kit used |
|---|---|---|---|---|---|---|---|---|
| Grutzmann et al., 2008 | 309 (126 CRC, 183 control) | 71.4% (90/126) | 89.6% (164/183) | 6.93 | 0.31 | 22.20 | 2/3 | Research kit |
| Lofton-Day et al.3 | 312 (133 CRC, 179 control) | 69% (92/133) | 86% (154/179) | 4.95 | 0.36 | 13.82 | 1/1 | Research kit |
| deVos et al.26 | 514 (187 CRC, 327 control) | 73.8% (138/187) | 86.2% (282/327) | 5.36 | 0.30 | 17.65 | 1/3 | Research kit |
| 56.1% (105/187) | 96.6% (316/327) | 16.69 | 0.45 | 36.78 | 2/3 | |||
| He et al., 2010 | 352 (182 CRC, 170 NED) | 74.7% (136/182) | 96.5% (164/170) | 21.17 | 0.26 | 80.81 | 1/1 | Research kit |
| Weiss and Rosch, 2010 | 257 (103 CRC, 154 NED) | 67.0% (69/103) | 87.7% (135/154) | 6.10 | 0.37 | 16.45 | 1/2 | Epi proColon 1.0 |
| Tanzer et al., 2010 | 67 (33 CRC, 34 control) | 82% (27/33) | 88% (30/34) | 6.95 | 0.21 | 33.75 | 1/3 | Epi proColon 1.0 |
| 73% (24/33) | 91% (31/34) | 8.24 | 0.30 | 27.56 | 2/3 | |||
| Warren et al., 2011 | 144 (50 CRC, 94 control) | 90.0% (45/50) | 88.0% (83/94) | 7.69 | 0.11 | 67.91 | 1/3 | ARUP Lab LDT assay |
| 76.0% (38/50) | 99.1% (93/94) | 71.44 | 0.24 | 294.50 | 2/3 | |||
| Ahlquist et al., 2012 | 73 (30 CRC, 43 control) | 60.0% (18/30) | 79.1% (34/43) | 2.87 | 0.51 | 5.67 | 1/3 | ARUP Lab LDT assay |
| Toth et al., 2012 | 184 (92 CRC, 92 control) | 95.6% (88/92) | 84.8% (78/92) | 6.29 | 0.05 | 122.57 | 1/3 | Epi proColon 2.0 |
| 79.3% (73/92) | 99% (91/92) | 73.00 | 0.21 | 349.63 | 2/3 | |||
| Wang et al., 2012 | 56 (36 CRC, 20 control) | 69.4% (25/36) | 90.0% (18/20) | 6.94 | 0.34 | 20.45 | 1/1 | research kit |
| Liu et al., 2013 | 57 (37 CRC, 20 control) | 54.1% (20/37) | 90.0% (18/20) | 5.41 | 0.51 | 10.59 | 1/2 | research kit |
| Church et al.7 | 1510 (53 CRC, 314 AA, 209 NAA, 934 NED) | 48.2% (27/53) | 91.5% (1333/1457) | 5.67 | 0.57 | 10.02 | 1/2 | Epi proColon 1.0 |
| 63.9% (34/53) | 88.4% (1288/1457) | 5.53 | 0.41 | 13.64 | 1/3 | |||
| Potter et al., 2014 | 1544 (44 CRC, 621 AA,435 SP, 444 NED) | 68.2% (30/44) | 80.0% (1200/1500) | 3.41 | 0.40 | 8.57 | 1/3 | Epi proColon 2.0 |
| Johnson et al.13 | 301 (101 CRC, 200 AA, SP and NED) | 73.3% (74/101) | 81.5% (163/200) | 3.96 | 0.33 | 12.07 | 1/3 | Epi proColon 2.0 |
| Toth et al., 2014 | 58 (34 CRC, 24 NED) | 88.2% (30/34) | 91.7% (22/24) | 10.59 | 0.13 | 82.50 | 2/3 | Epi proColon 2.0 |
| Kang et al.21 | 132 (80 CRC, 52 NED) | 75.0% (60/80) | 98.1% (51/52) | 39.00 | 0.25 | 153.00 | 2/3 | Epi proColon 2.0 |
| He et al., 2014 | 281 (76 CRC, 69 Polyps, 136 NED) | 71.1% (54/76) | 95.6% (196/205) | 16.18 | 0.30 | 53.45 | 2/3 | Epi proColon 2.0 |
| Jin et al.23 | 226 (135 CRC, 91 control) | 74.8% (101/135) | 96.7% (88/91) | 22.69 | 0.26 | 87.14 | 2/3 | Epi proColon 2.0 |
| Yu et al., 2015 | 123 (70 CRC, 53 NED) | 81.4% (57/70) | 86.8% (46/53) | 6.17 | 0.21 | 28.81 | 2/3 | Epi proColon 2.0 |
| Ørntoft et al., 2015 | 278 (128 CRC, 150 NED) | 72.7% (93/128) | 82.0% (123/150) | 4.04 | 0.33 | 12.10 | 1/3 | Epi proColon 2.0 |
| 58.6% (75/128) | 95.3% (143/150) | 12.47 | 0.43 | 28.91 | 2/3 | |||
| Li et al., 2015 | 138 (91 CRC, 47 NED) | 72.5% (66/91) | 91.5% (43/47) | 8.53 | 0.30 | 28.38 | 1/1 | SensiColon |
| He et al., 2015 | 100 (50 CRC, 50 NED) | 76.0% (38/50) | 96.0% (48/50) | 19.00 | 0.25 | 76.00 | 1/1 | Research kit |
| Ding et al.25 | 182 (82 CRC, 100 NED) | 73.2% (60/82) | 96.0% (96/100) | 18.30 | 0.28 | 65.45 | 2/3 | Epi proColon 2.0 |
| Wu et al.10 | 586 (291 CRC, 295 NED) | 76.6% (223/291) | 95.9% (283/295) | 18.84 | 0.24 | 77.34 | 1/1 | SensiColon |
| Song et al.11 | 859 (369 CRC, 490 NED) | 82.4% (303/369) | 82.0% (402/490) | 4.58 | 0.21 | 20.97 | 1/3 | Epi proColon 2.0 |
| 75.1% (277/369) | 97.1% (476/490) | 25.90 | 0.26 | 102.37 | 2/3 |
PLR = positive likelihood ratio, NLR = negative likelihood ratio, OR = odds ratio, CRC = colorectal cancer, NED = no evidence of diseases, AA = advanced adenoma, NAA = non-advanced adenoma, SP = small polyps, LDT = laboratory developed test.